Halo Labs (formerly Optofluidics) is a venture backed scientific instrumentation company that commercializes high throughput biopharmaceutical quality control tools using the latest optics, image processing and microfluidics.
Since being founded in the summer of 2010 by Professor David Erickson from Cornell University, Halo Lab’s core mission has been to provide researchers with unprecedented insights into the particles present in their processes by leveraging our core scientific competency: novel optics. Over the years Halo Labs has been the recipient of many prestigious awards, including Philadelphia’s Life Science Startup of 2012 and the Pittcon Silver Product Award; and have been recipients to over $6M in research grants from agencies including DARPA, FDA, NSF, NIST and NIH. Today, we dedicate our collective experience and novel technology to empower formulation researchers to learn more about the stability and quality of their biological drugs faster and with more accuracy than ever before.
Our institutional partners include BioAdvance, the Ben Franklin Technology Partners of South Eastern Pennsylvania and Broad Oak Capital Partners.